Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:3020-3030
Published online before print June 2, 2008, doi: 10.1161/CIRCULATIONAHA.108.769646
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
117/23/3020    most recent
CIRCULATIONAHA.108.769646v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Diller, G.-P.
Right arrow Articles by Wharton, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diller, G.-P.
Right arrow Articles by Wharton, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
Medline Plus Health Information
*Pulmonary Hypertension
*Stem Cells
Related Collections
Right arrow Pulmonary circulation and disease
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Pediatric and congenital heart disease, including cardiovascular surgery
Right arrow Pulmonary biology and circulation
Right arrowRelated Article

(Circulation. 2008;117:3020-3030.)
© 2008 American Heart Association, Inc.


Vascular Medicine

Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension

Gerhard-Paul Diller, MD; Sven van Eijl, PhD; Darlington O. Okonko, MRCP; Luke S. Howard, MRCP; Omar Ali, MRCP; Thomas Thum, MD; Stephen J. Wort, MRCP; Elisabeth Bédard, FRCPC; J. Simon R. Gibbs, FRCP; Johann Bauersachs, MD; Adrian J. Hobbs, PhD; Martin R. Wilkins, FRCP; Michael A. Gatzoulis, PhD; John Wharton, PhD

From the Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK (G.-P.D., E.B., S.J.W., M.A.G.); National Heart and Lung Institute (G.-P.D., D.O.O., J.S.W., M.A.G., J.S.R.G., L.S.H) and Department of Experimental Medicine and Toxicology (S.v.E., O.A., M.R.W., J.W.), Imperial College London, London, UK; Julius-Maximilians-Universität, Medizinische Klinik I, Würzburg, Germany (T.T., J.B); National Pulmonary Hypertension Service, Hammersmith Hospital, London, UK (L.S.H., S.R.G.); and Wolfson Institute for Biomedical Research, University College London, London, UK (A.J.H).

Correspondence to Gerhard-Paul Diller, MD, Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. E-mail g.diller{at}imperial.ac.uk

Received May 14, 2007; accepted March 7, 2008.

Background— Impaired endothelial homeostasis underlies the pathophysiology of pulmonary arterial hypertension (PAH). We speculated that PAH patients are deficient in circulating endothelial progenitor cells (EPCs), potentially contributing to endothelial dysfunction and disease progression.

Methods and Results— We recruited 41 patients with Eisenmenger syndrome (13 with Down syndrome), 55 with idiopathic PAH, and 47 healthy control subjects. Flow cytometry and in vitro assays were used to quantify EPCs and to assess cell function. The number of circulating CD34+, CD34+/AC133+, CD34+/KDR+, and CD34+/AC133+/KDR+ progenitor cells was low in Eisenmenger patients compared with healthy control subjects, and those with Down syndrome displayed even fewer EPCs. Reductions in EPC numbers correlated with New York Heart Association functional class, 6-minute walk distance, and plasma brain-type natriuretic peptide levels. The capacity of cultured peripheral blood mononuclear cells to form colonies and incorporate into tube-like structures was impaired in Eisenmenger patients. Idiopathic PAH patients had reduced numbers of EPCs, and the number of circulating EPCs correlated with invasive hemodynamic parameters in this cohort. Levels of immune inflammatory markers, cGMP, stable nitric oxide oxidation products, and asymmetric dimethylarginine were abnormal in patients with PAH and related to numbers of EPCs. Within the idiopathic PAH population, treatment with the phosphodiesterase inhibitor sildenafil was associated with a dose-dependent rise in EPC numbers, resulting in levels consistently above those found with other therapies.

Conclusions— Circulating EPC numbers are reduced in 2 well-characterized forms of PAH, which also exhibit raised levels of inflammatory mediators. Sildenafil treatment may represent a pharmacological means of increasing circulating EPC numbers long-term.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 2961-2962. [Full Text]